Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jon Jureidini (jureidinij@wch.sa.gov.au), head,
  2. Anne Tonkin, associate professor, department of clinical and experimental pharmacology,
  3. Peter R Mansfield, research fellow, department of general practice
  1. Department of Psychological Medicine, Women's and Children's Hospital, North Adelaide 5006, Australia
  2. University of Adelaide, Adelaide 5005, Australia

    EDITOR—We have additional concerns to those raised by Lenzer about the adolescents with depression study (TADS).1 2

    TADS consists of two separate randomised studies: a double blind comparison of fluoxetine (109 subjects) with placebo (112), and an unblinded comparison between cognitive behaviour therapy alone (111) and fluoxetine plus cognitive behaviour therapy (107). The lack of patient blinding and placebo control in the latter group is likely to exaggerate the benefit seen in the fluoxetine plus cognitive behaviour therapy group, who receive more face to …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular